Cryptococcus neoformans is an opportunistic fungal pathogen that usually infects the host via the lungs and then disseminates to the central nervous system, where it can cause life-threatening disease in immunocompromised patients. Immunocompetent individuals generally clear the pulmonary infection, although an outbreak of infections with C. gattii serotype B in apparently immunocompetent individuals on Vancouver Island, Canada, and in the surrounding areas occurred recently (21) .
Outside the cell wall, which contains chitin and chitosan (5), ␣-1,3-glucans (48) , and ␤-1,3-and ␤-1,6-glucans (28), C. neoformans elaborates a polysaccharide capsule composed primarily of the polysaccharide glucuronoxylomannan (GXM). Minor capsular components include galactoxylomannan (GalXM) and mannoprotein 1 (MP1). The capsule is a key virulence factor, with myriad roles including antiphagocytic activities (29) and immunomodulatory functions during adaptive immune responses (15, 46, 61) . Interestingly, the capsule has also been shown previously to be important for dissemination from the lungs (9) , and the capsular component GalXM has been shown to facilitate dissemination to the central nervous system (44) . The capsule also plays a prominent role during interactions of C. neoformans with macrophages (7, 29, 33, 51) . Consequently, it is of fundamental interest to understand the role of capsular components in C. neoformans clearance by innate immune cells in the lungs.
Surfactant is a lipid-rich material that has been recognized traditionally to be essential for reducing surface tension in the lungs but, more recently, has been appreciated as orchestrating important innate immune functions (60) . Surfactant is synthesized primarily by type II cells of the aveoli, although surfactant proteins (SPs) are also produced by cells of the distal airways. In addition to lipids, there are four SPs, designated SP-A, SP-B, SP-C, and SP-D. SP-B and SP-C are hydrophobic and remain closely associated with the lipid component of surfactant, participating in its surface tension-lowering ability and biophysical properties. SP-A and SP-D are more hydrophilic and have important innate immune functions as a result of their abilities to evoke both proinflammatory and anti-inflammatory responses (23) . These dual functions of SP-A and SP-D depend on their structures, which include a C-terminal carbohydrate recognition domain (CRD) and an N-terminal collagen-like region. SP-A and SP-D are members of the collectin family of proteins, which bind via their CRDs in a calcium-dependent manner to sugars present on the surfaces of microorganisms, allowing SP-A and SP-D to function as pattern recognition molecules. Via binding to the carbohydrate moieties of many different microorganisms, collectins opsonize and enhance the phagocytosis of microbial pathogens (6, 30, 32, 47) .
To date, relatively little is known about the role played by SPs during innate immune responses to C. neoformans infection. Both SP-A and SP-D have been observed to bind to acapsular strains, resulting in their aggregation (50) . Although SP-A binds to C. neoformans, it does not enhance its uptake (58) , and the susceptibility of SP-A null mice to C. neoformans infection is similar to that of wild-type animals, suggesting that SP-A does not play a major role in C. neoformans host defense in vivo (26) . SP-D, but not SP-A, binds MP1 and GXM in vitro, and GXM has been shown previously to inhibit the SP-Ddependent aggregation of C. neoformans cells (55) . In addition, SP-D interacts with ␤-1,6-glucan present in the cell walls of Saccharomyces cerevisiae and Aspergillus fumigatus (2) . It is of interest that exogenous SP-D administration is protective in a mouse model of invasive aspergillosis (52) . Additionally, SP-D is important for mounting an appropriate immune response to a number of different fungal pathogens, including A. fumigatus (40, 41) and Pneumocystis carinii (4) , although any physiological role during the initial stages of C. neoformans infection remains unclear. We hypothesized that SP-D plays a role in the early phase of C. neoformans infection by binding to and enhancing the phagocytosis of the yeast.
Here, we characterize SP-D binding to the acapsular C. neoformans cap59⌬ strain and the isogenic wild-type strain H99 and demonstrate that SP-D enhances C. neoformans phagocytosis in vitro and in vivo. Paradoxically, we show that the pretreatment of C. neoformans with SP-D results in increased fungal growth in the presence of macrophages. The findings presented here expand our understanding of the role of SP-D in initial pulmonary immune responses to the fungus and may lead to novel therapies for patients presenting with pulmonary cryptococcal infections.
MATERIALS AND METHODS

Animals and reagents.
Experiments were conducted using specific-pathogenfree C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME) and SP-D Ϫ/Ϫ mice with the same background, generated as described previously (20, 59) ; the ages of the mice ranged between 6 and 8 weeks. Animals were anesthetized by intraperitoneal injection with 150 mg/kg ketamine (Fort Dodge Animal Health, Fort Dodge, IA) and 10 mg/kg xylazine (Lloyd Laboratories, Shenandoah, IA) and sacrificed by intraperitoneal injection with pentobarbital (Nembutal; Abbot Laboratories, North Chicago, IL), followed by exsanguination. All procedures were approved by the Duke University Institutional Animal Care and Use Committee.
Isolation of human SP-A from alveolar proteinosis patients and isolation of recombinant SP-D. SP-A was isolated from human bronchoalveolar lavage samples via butanol extraction as described previously (43) . Recombinant SP-D was isolated from Chinese hamster ovary cells expressing a clone of the full-length rat SP-D gene, purified using maltose affinity chromatography, and stored at 4°C in 5 mM Tris buffer, pH 7.8, containing 2 mM EDTA as described previously (14) .
Culturing and maintenance of C. neoformans strains. C. neoformans serotype A strains H99␣ and KN99␣, the cap59⌬::HYG mutant (H99 background) (45) , and the cap59⌬::NAT mutant (KN99 background) and serotype D strain B3501 and the cap67⌬ mutant (ATCC 52817) were maintained in glycerol stocks. Stocks of wild-type and mutant strains were grown on yeast extract-peptonedextrose (YPD) agarose and YPD plus hygromycin or nourseothricin agarose, respectively, and incubated at 30°C. Liquid cultures were grown in YPD medium at 30°C for 16 to 18 h in a shaking incubator at 250 rpm.
Culturing and maintenance of J774A.1 macrophages. The J774A.1 murine macrophage cell line (ATCC, Manassas, VA) was cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (HyClone, Logan, UT) and 100 U/ml of penicillin-streptomycin in T75 flasks and subcultured by scraping and dilution at a ratio of 1:6. Cells were maintained at 37°C in an atmosphere containing 5% CO 2 . Assays performed with macrophages were carried out in the absence of serum to distinguish the effects of SP-D alone.
AF488 fluorescent labeling of SPs. Human SP-A and rat recombinant SP-D were labeled with fluorescent dyes with an Alexa Fluor 488 (AF488) proteinlabeling kit (Invitrogen, Carlsbad, CA). SP-A (2 mg/ml) in a volume of 500 l was dialyzed against 1 liter of 5 mM HEPES, pH 6.4, before labeling to remove EDTA and against Tris-buffered water (5 mM; pH 7.4) after labeling to remove unbound fluorescent dye. SP-D was dialyzed against phosphate-buffered saline (PBS) without Ca 2ϩ or Mg 2ϩ before and after labeling. In addition, the pH for the labeling reaction was raised by dialyzing SP-D against 0.1 M sodium bicarbonate, pH 9.0, for 3 h prior to labeling. All proteins had labeling efficiencies of 5 to 15 Alexa molecules/protein monomer. The functionalities of labeled SP-A and SP-D were assessed by their abilities to bind to Escherichia coli K-12.
SP-D binding to C. neoformans strains. C. neoformans strains were centrifuged at 2,000 ϫ g for 2 min, washed three times, and resuspended in sterile PBS containing 0.9 mM CaCl 2 and 0.1% bovine serum albumin (BSA). C. neoformans cells were counted with a hemocytometer and adjusted to a concentration of 10 6 yeast cells/ml. For binding assays, aliquots of 100 l (10 5 yeast cells) of this suspension were used. SP-D binding to C. neoformans strain H99 and the cap59⌬ mutant was assessed at a protein concentration of 0.1 g/ml in PBS-0.9 mM CaCl 2 containing 0.1% BSA (Sigma-Aldrich, St. Louis, MO) to block nonspecific binding. Strains were incubated with SP-D in 1.5-ml microcentrifuge tubes for 1 h at 37°C with shaking in a thermomixer (model no. 5436; Eppendorf, Westbury, NY) in the dark and were then assessed by flow cytometry and fluorescence microscopy.
Flow cytometry. Binding reaction mixtures were removed to 5-ml polystyrene round-bottom fluorescence-activated cell sorter tubes (BD Biosciences Discovery Labware, Franklin Lakes, NJ) for analysis. Results were obtained using an LSR II flow cytometry system (BD Biosciences, San Jose, CA). The analysis of results was performed using the FlowJo software (Treestar Inc., Ashland, OR). Prior to SP-D binding analysis, C. neoformans cells were gated using plots of the forward scatter height versus the forward scatter area so as to exclude aggregates, and at least 10,000 events were assessed. Data represent experiments that were performed at least three times, with similar results.
Light and fluorescence microscopy. Fluorescence microscopy was performed using an Axioskop 2 Plus fluorescent microscope (Carl Zeiss Microimaging Inc., Thornwood, NY) with an attached AxioCam MRM digital camera. All images were acquired at a fixed time exposure. Data represent experiments performed at least three times, with similar results.
Sugar competition for SP-D binding. All reagents were obtained from SigmaAldrich (St. Louis, MO) unless otherwise stated. MP1 was a kind gift from Frank Coenjaerts (University Medical Center Utrecht, Utrecht, The Netherlands), and GXM was a kind gift from Thomas Mitchell (Duke University, Durham, NC). All sugars were solubilized in PBS at concentrations of 2 mg/ml and added to SP-D binding assay mixtures at the concentrations indicated in Fig. 4 . Sugar competitors were added to SP-D samples prior to the addition of C. neoformans cells to obtain optimal interactions between SP-D and each competitor evaluated. Results were assessed by flow cytometry. Data represent experiments that were performed at least three times, with similar results.
Uptake of C. neoformans cells by J774A.1 macrophages. J774A.1 cells were removed from T75 flasks by scraping, centrifuged at 1,000 ϫ g for 8 min, and resuspended in complete medium. Live cells were counted with a hemocytometer using trypan blue exclusion to identify dead cells. Cells were then adjusted to a concentration of 10 5 cells/ml. Samples of 300 l of this suspension were added to eight-well chamber culture slides (Nalge Nunc International, Rochester, NY), and the slides were incubated overnight prior to C. neoformans challenge. Cells were either infected immediately or activated with lipopolysaccharide (LPS) and gamma interferon for 3 h prior to infection for the trafficking and immunofluorescence assays, as described below. C. neoformans cells were washed three times and resuspended in complete medium, counted with a hemocytometer, and adjusted to a concentration of 3 ϫ 10 5 yeast cells/ml to achieve a multiplicity of infection (MOI) of 5:1. SP-D was used at a concentration of 1 g/ml, and pustulan was used at a concentration of 25 g/ml. C. neoformans cells were preincubated alone or with SP-D, SP-D and pustulan, or pustulan alone in PBS-0.9 mM CaCl 2 -0.1% BSA for 1 h at 37°C, centrifuged, and resuspended in complete medium. Preincubated yeast cells were then added to macrophages at time zero of time-lapse microscopy experiments. Data represent experiments that were performed at least three times, with similar results.
In vivo uptake of C. neoformans cells by wild-type and SP-D ؊/؊ mouse macrophages. AF488-labeled cap59⌬ or H99 cells were intranasally instilled into anesthetized wild-type and SP-D Ϫ/Ϫ mice at a concentration of 5 ϫ 10 5 cells/ mouse. This large inoculum was selected to ensure that sufficient numbers of C. neoformans cells were retrieved for quantification by confocal microscopy and 2784 GEUNES-BOYER ET AL. INFECT. IMMUN.
also to mimic the MOI employed in the in vitro uptake studies. Twelve hours postinfection, mice were harvested by lethal injection with sodium pentobarbital, followed by exsanguination. The lungs were lavaged using a 20-gauge cannula to inject a PBS solution containing 0.2 mM EGTA. Lungs were inflated to full capacity (equivalent to approximately 1 ml of buffer) three times, and the cells obtained were centrifuged at 1,000 ϫ g for 10 min at 4°C. The cells were then resuspended in macrophage medium, plated onto eight-well chamber slides (Nalge Nunc International, Rochester, NY), and allowed to adhere for 2 h. The chamber slides were then placed on ice for 20 min prior to macrophage membrane labeling. Membrane labeling was performed by washing the macrophages three times with PBS-Ca 2ϩ , incubating them in blocking solution (10% mouse serum and 2% BSA in SuperBlock buffer [Pierce]) for 1 h on ice, and then incubating them with allophycocyanin-conjugated hamster anti-mouse CD11c (BD Biosciences, San Jose, CA) in blocking solution for 1 h on ice. The washing step was repeated, and the cells were fixed in 1% formalin in PBS. The slides were then mounted with FluorSave reagent (Calbiochem, San Diego, CA), and the results were assessed by confocal microscopy.
Preparation of C. neoformans cells for macrophage trafficking and yeast growth assays. C. neoformans cells were grown overnight in YPD liquid medium, spun down at 2,000 ϫ g, washed three times, and labeled with AF647 dye, which binds primary amines on the yeast cell surface. The yeast were then washed again three times with PBS to remove any unconjugated Fluor and resuspended at a concentration of 2 ϫ 10 6 yeast cells/ml in a sterile PBS solution containing 0.9 M CaCl 2 . Yeast cells were then incubated with 1 g/ml SP-D or incubated alone for 1 h at 37°C with shaking in a thermomixer (model no. 5436; Eppendorf, Westbury NY). For macrophage infection, 10-l aliquots of pretreated yeast cells (20,000 yeast cells each) were inoculated into wells containing activated macrophages. This number of yeast cells was chosen to represent an MOI of 1:1, with the assumption that the macrophages had doubled overnight (56) . For the immunofluorescence studies, an MOI of 5:1 was used so that sufficient yeastcontaining macrophages could be assessed.
Immunofluorescence. Samples of 300 l of a suspension containing J774A.1 macrophages were plated into eight-well coverslip chambers at a concentration of 10 5 cells/ml, and the cells were allowed to adhere overnight and were activated for 3 h with 300 l of fresh complete medium containing 100 ng/ml LPS (serotype 0111:B4) and 200 U/ml mouse gamma interferon (R&D Systems). Activated cells were then infected with SP-D-bound or unbound AF647-labeled cap59⌬ yeast cells for 16 h, washed three times with PBS, fixed with 4% paraformaldehyde for 20 min at room temperature, and then washed three more times with PBS and permeabilized with Ϫ20°C methanol for 1 min. Macrophages were then washed three times with PBS and incubated in blocking solution (10% goat serum and 2% BSA in SuperBlock [Pierce]) for 1 h at 37°C. Next, the macrophages were incubated with monoclonal rat anti-mouse CD107a (LAMP-1) primary antibody (Pharmingen) at a final concentration of 1 g/ml for 30 min at 37°C, washed three times with blocking solution, and incubated with AF488-labeled goat anti-rat secondary antibody (Invitrogen), diluted 1:2,500, for 30 min at 37°C. Macrophages were then washed three times with PBS and viewed by confocal microscopy.
Assays of macrophage inhibition of yeast cell growth. J774A.1 macrophages were counted with a hemocytometer using trypan blue to exclude dead cells and resuspended at a concentration of 10 5 cells/ml, and aliquots of 100 l (10,000 cells) of this suspension were plated into a 96-well plate. Macrophages were allowed to adhere overnight, and then the medium was replaced with 100 l of fresh complete medium containing 100 ng/ml LPS (serotype 0111:B4) and 200 U/ml mouse gamma interferon (R&D Systems) for 3 h to activate the cells. An additional 100 l of complete medium was then added to the cells, and pretreated C. neoformans yeast cells were added to the macrophages at an MOI of 1:1. Controls included wells containing macrophages alone and C. neoformans cells alone under each pretreatment condition. The growth of the yeast cells after 16 h was assessed by removing the supernatant from each well and lysing the macrophages with two washes in 100 l of 0.01% sodium dodecyl sulfate in PBS. The supernatant and sodium dodecyl sulfate wash fluid for each condition were combined, and dilution series were plated onto YPD agarose plates for CFU analysis. Results were assessed by comparing the numbers of CFU from cultures of macrophages and C. neoformans cells to that from each of the respective control cultures with C. neoformans cells alone. This approach allowed us to normalize for growth rate differences among different strains as well as, potentially, SP-D preopsonization. Experiments were performed in replicates of five, and the results presented represent data obtained in at least three independent experiments.
Time-lapse microscopy. Time-lapse microscopy was performed using an Axiovert time-lapse station (Carl Zeiss Microimaging Inc., Thornwood, NY) equipped with an Orca AG camera (Hamamatsu, Bridgewater, NJ). An exposure of 240 ms, along with a long-distance acroplan 40ϫ objective, was used for optimal bright-field cell imaging. Images of five independent fields in each well were obtained at 1-min intervals for a total of 120 min.
Confocal microscopy. Confocal microscopy was performed with the laserscanning microscope model 510 Meta (Carl Zeiss Microimaging Inc., Thornwood, NY). Images were acquired at oil immersion magnifications of ϫ20 and ϫ100 by using the 488-and 633-nm lasers for green and red fluorescence, respectively. XZ-stacks at a magnification of ϫ100 were generated.
Statistics. Data were subjected to the two-tailed Student t test to compare two groups, one-way analysis of variance followed by Tukey's multiple-comparison test to compare more than two groups, and two-way analysis of variance followed by the Bonferroni posttest to compare multiple conditions. Statistics were calculated using the Microsoft Excel software package and GraphPad Prism 5.0a. Analyses with resulting P values of Ͻ0.05 were considered to demonstrate statistical significance. . SP-D binds to a much greater extent to cap59⌬ mutant cells than to isogenic wildtype cells. When C. neoformans cells were grown under standard conditions (overnight in YPD at 30°C), SP-D bound to H99 cells in a punctate pattern whereas binding to cap59⌬ cells was uniform and intense, as observed by fluorescence microscopy ( Fig. 1 and 2 ). This same pattern of enhanced binding to the hypocapsular mutant was observed in the comparisons between wild-type KN99 and the isogenic cap59⌬::NAT mutant and, to a lesser extent, between wild-type B3501 and the cap67⌬ mutant (Fig. 2C) . These findings suggest that the absence of capsular GXM on cap59⌬ cells may expose avid SP-D binding partners closely associated with the C. neoformans cell wall and that the polysaccharide capsule inhibits SP-D binding. These interpretations are further reinforced by the observation that the binding of SP-D to some wild-type daughter cell buds, which may not yet have assembled appreciable capsular material and/or may possess a capsule architecture that differs from that of the mother cell, is enhanced compared to binding to the mother cell (Fig. 3, inset) . In summary, SP-D binding is inhibited by GXM, and binding to cells with reduced GXM levels is enhanced (Fig. 3) .
RESULTS
SP-D, but not SP-
To (19) . GXM is the major capsular component of C. neoformans cells (24) , and MP1 is a minor capsular component (34, 36) . Pustulan, GXM, and MP1 each inhibited SP-D binding to H99 and cap59⌬ cells in a dose-dependent manner at different concentration ranges, with pustulan being the most effective inhibitor (Fig. 4) . The superior ability of pustulan, a cell wall component, to compete for SP-D binding correlates with the avid interaction observed between SP-D and cap59⌬ cells. The cap59⌬ deletion mutants have no GXM on their surfaces (22) and therefore present more-exposed cell walls, which we hypothesize results in an enhanced ability of SP-D to interact with cell wall-associated ␤-glucans. We were unable to detect any competition for SP-D binding from lam- To test the hypothesis that SP-D interacts with more than one ligand on the surfaces of C. neoformans cells, we examined the abilities of GXM, MP1, and pustulan to inhibit SP-D binding to the encapsulated H99 strain and the acapsular cap59⌬ mutant. We found that all competitors, as well as many sugars known to bind the CRD domain of SP-D with variable affinities (11, 12, 37) , inhibited SP-D binding to H99 cells to a much greater extent than that to cap59⌬ cells (Fig. 4) . The abilities of combinations of GXM, MP1, and pustulan to compete with SP-D binding to C. neoformans were also assessed by fluorescence microscopy and flow cytometry. We were unable to dis- Finally, we examined the abilities of SP-D to bind to various C. neoformans deletion strains lacking specific cell wall-and capsule-associated gene products. We found that C. neoformans strains containing mutations that affect mannosylation and ␤-glucan synthesis exhibited decreased SP-D binding and that those with mutations that compromise capsular integrity demonstrated increased SP-D binding compared to wild-type strains (Table 1) . These results further support the hypotheses that the capsule impedes SP-D binding and that ␤-glucans and mannose residues on the surfaces of C. neoformans cells interact with SP-D. Interestingly, the uge1⌬ and ugt1⌬ mutants, which are GalXM negative (44) , showed binding levels equivalent to that of the isogenic wild-type control, excluding GalXM on the surfaces of C. neoformans cells as an SP-D binding partner.
SP-D opsonization of cap59⌬ cells enhances phagocytosis by macrophages in vitro, and SP-D null mice exhibit reduced phagocytosis of cap59⌬ and H99 cells in vivo.
To assess the ability of SP-D to enhance the phagocytosis of C. neoformans by macrophages, C. neoformans cells were preincubated with SP-D alone, SP-D and the competitor pustulan, pustulan alone, or neither SP-D nor pustulan and then incubated with adherent J774A.1 cells at an MOI of 5:1. The presence or absence of SP-D on the surfaces of C. neoformans cells was determined using a rabbit anti-mouse SP-D primary antibody and AF594-conjugated goat anti-rabbit secondary antibody, and the results were assessed by flow cytometry (data not shown). Phagocytosis was analyzed by time-lapse microscopy for a duration of 2 h. H99, either alone or opsonized with SP-D and in the presence of preactivated macrophages or those with no pretreatment, was not detectably phagocytosed in vitro (data not shown), consistent with data from previous reports establishing that the capsule inhibits uptake by innate immune cells in vitro (7, 29, 53) . In contrast, the cap59⌬ strain was phagocytosed at a low basal level even when no opsonin was present (see . When macrophages were preactivated with LPS and gamma interferon, results similar to those described above were observed at 1 and 2 h postinfection ( Fig. 5C and D) , although the phagocytic index was increased about fourfold for all treatments evaluated. Therefore, SP-D acts as an opsonin for acapsular C. neoformans cells and results in an increase in the number of macrophages phagocytosing fungal cells, as well as a higher rate of phagocytosis by both unactivated and activated macrophages. In accordance with the findings in an earlier report (13) , primary rat alveolar macrophages (AMs) did not phagocytose either unopsonized or SP-D-opsonized cap59⌬ or H99 cells (data not shown).
To assess the uptake of C. neoformans cap59⌬ and H99 cells in vivo in wild-type and SP-D Ϫ/Ϫ mice, both C. neoformans strains were fluorescently labeled with AF488 and intranasally instilled into the mice at 500,000 yeast cells per animal. Lungs were lavaged, and cells were allowed to adhere to chamber slides and examined by confocal microscopy. AMs from wildtype mice contained approximately threefold more internalized cap59⌬ cells and threefold more H99 cells than did AMs from SP-D Ϫ/Ϫ mice (Fig. 6 ). Uptake was quantified by calcu- (C) Mean 50% inhibitory concentrations (I 50) of the competitors. * , P Ͻ 0.05; ** , P Ͻ 0.01. The results shown represent data obtained from at least three independent experiments. Data were analyzed using two-way analyses of variance, followed by Tukey's multiplecomparison test and the two-tailed Student t test. A P value of Ͻ0.05 was considered significant. lating the phagocytic index for the two groups as described above. SP-D was shown to bind to AF488-labeled cap59⌬ cells by preincubating these cells with 1 g/ml of SP-D, detecting bound SP-D by using a rabbit anti-mouse SP-D primary antibody and an AF594-conjugated goat anti-rabbit secondary antibody, and assessing the results by flow cytometry (data not shown). In summary, we found that SP-D augments the phagocytosis of hypocapsular C. neoformans cells by mouse macrophages in vitro and in vivo.
SP-D-bound cap59⌬ cells traffic to lysosomal compartments but demonstrate decreased colocalization with LAMP-1 and decreased breakdown compared to unbound cap59⌬ cells in vitro. The trafficking of cap59⌬ cells to LAMP-1-positive compartments in J774A.1 cells, with or without preopsonization with SP-D, was assessed. cap59⌬ cells trafficked to phagolysosomal compartments in the presence or absence of SP-D pretreatment. However, when SP-D was present, fewer cap59⌬ cells colocalized with LAMP-1 and significantly fewer fluorescent cell wall fragments were detected. Trafficking was assessed by incubating AF647-labeled cap59⌬ cells with J774A.1 macrophages at an MOI of 10:1 for 16 h and visualizing lysosomal compartments by immunofluorescence using rat antimouse CD107a (LAMP-1) primary antibody, followed by AF488-labeled goat anti-rat secondary antibody. Colocalization was qualitatively ascertained by confocal microscopy and quantitated with the Metamorph software. The results showed decreased colocalization of SP-D-bound cap59⌬ cells with LAMP-1 compared to that of unbound yeast cells (Fig. 7A and  B) . Furthermore, we observed greater breakdown of unbound than of SP-D-bound cap59⌬ cells (Fig. 7C) . (Fig. 8) .
DISCUSSION
Although the lung collectins SP-A and SP-D have been shown to opsonize a variety of pathogens, few studies have a Binding differences among independent kre5⌬, kre6⌬ skn1⌬, cas35⌬, cas33⌬, and cap59⌬ mutants were confirmed. The other mutants included in the table are of interest, although neither independent nor complemented strains were available. A selection of mutant strains not demonstrating significant SP-D binding differences compared to the background binding levels of controls include those with the following mutations (in genes encoding the indicated processes or products): ilv5⌬ (isoleucine/valine biosynthesis), crr1⌬ (cell wall organization and biogenesis-related protein), chs2⌬ (putative chitin synthase 2), uge1⌬ (UDP-glucose epimerase), ugt1⌬ (UDP-galactose transporter), myo10⌬ (putative myosin heavy chain b), mpn5⌬ (putative nuclear protein), and pep4⌬ (putative endopeptidase). narin, and monosaccharides to compete for SP-D binding were examined. Although laminarin demonstrated no competitive ability, pustulan, GXM, and MP1 all inhibited SP-D binding in a dose-dependent manner, and pustulan was the most effective competitor. This finding is consistent with the observed high level of SP-D binding to cap59⌬ cells, which probably have a larger amount of ␤-(1,6)-glucan exposed on the surface than cells of encapsulated strains such as H99. The ability of GXM to inhibit SP-D binding is curious since our observations suggest that the presence of the capsule, which is composed predominantly of GXM, is inversely related to SP-D binding. We hypothesize that isolated GXM binds to and inhibits the interaction of SP-D with another C. neoformans component or that the purified GXM used in the inhibition assays displays an SP-D binding epitope that is not available in the context of the intact encapsulated yeast cell. Because SP-D binds to acapsular C. neoformans cells to a much greater extent than to wild-type encapsulated H99 cells, we speculate that capsule formation hinders SP-D activity and inhibits binding to cell wall components. This hypothesis is reinforced by our observation that various cell wall and capsule mutants demonstrate decreased and increased SP-D binding, respectively. The polysaccharide capsule of C. neoformans cells has been proposed previously to be a major virulence factor, and the predominant capsular polysaccharide, GXM, has been shown to be antiphagocytic (29) and to inhibit immune responses by downregulating proinflammatory cytokine production and inhibiting neutrophil chemotaxis (10, (16) (17) (18) 57) . Our results are consistent with the hypothesis that the absence of capsular GXM on cap59⌬ cells allows for greater SP-D binding to cell wall components of the hypocapsular yeast. Because the initial infection in the lungs is thought to be caused by desiccated yeast cells or basidiospores, which are postulated to have reduced capsule levels, we hypothesize that SP-D is important for immediate opsonization of the infectious propagule, which thereby results in increased phagocytosis by resident AMs. SP-D may play an important role during the initial stages of C. neoformans cellular infection, as we found that SP-D opsonizes the surfaces of hypocapsular C. neoformans cells, resulting in an increased rate of uptake by a macrophage cell line, as well as an increased overall phagocytic index. In addition, after intranasal instillation of fluorescently labeled C. neoformans cap59⌬ or H99 cells, AMs obtained from wild-type mice, replete with SP-D, contained more intracellular C. neoformans cells than AMs from SP-D Ϫ/Ϫ mice. The decreased phagocytosis in the SP-D null mice may be a consequence of the lack of opsonic function of SP-D. However, it is also possible that the reduced uptake is a consequence of the previously reported altered macrophage function in SP-D null mice (25) Our data support the possibility that SP-D plays a role in opsonizing and protecting C. neoformans cells during the initial stages of C. neoformans infection. Whether or not disease outcome is affected remains to be determined, and we are currently examining disease progression in the murine model. Because C. neoformans is a facultative intracellular pathogen, it is possible that C. neoformans may use SP-D as a Trojan horse to gain access to specific intracellular compartments FIG. 7 . SP-D opsonization decreases cap59⌬ cell colocalization with LAMP-1 and decreases fungal breakdown. Lysosomal trafficking of SP-D-bound or unbound AF647-labeled cap59⌬ cells was assessed by immunofluorescence and confocal microscopy analyses. The percent colocalization and percent debris were determined using the colocalization and regions tools, respectively, in Metamorph software. The percent debris was obtained by creating regions around intact cap59⌬ cells in the red channel and subtracting the resultant value from the number of all red pixels present for a given image to obtain the pixel value for debris. This value was then divided by the total number of red pixels and multiplied by 100 to obtain a percentage. Results were obtained by assessing 15 randomly selected cells under each condition and are presented as the means Ϯ standard errors. Similar results were obtained from two experiments performed in triplicate. Data were analyzed using the two-tailed Student t test, and a P value of Ͻ0.05 was considered significant. Scale bars, 5 m. DIC, differential interference contrast image; Cn, C. neoformans; ϩ, with; Ϫ, without.
where it can grow and divide in intracellular vesicles (31, 35, 54) . In the present work, LAMP-1 staining indicated that both SP-D-opsonized and unopsonized cap59⌬ cells were targeted to LAMP-1-positive compartments, although the presence of SP-D protected the yeast cells against immune cell antimicrobial effects, as evidenced by a reduction in yeast cell debris. In fact, C. neoformans cells have been shown previously to initiate a phagosomal extrusion event, resulting in their extracellular release (3, 39) . In addition, it has been postulated that C. neoformans cells disseminate from the pulmonary space via transport by phagocytic immune cells (8, 38, 49) . Thus, the effects of SP-D may allow for sufficient intracellular fungal growth and, potentially, increased dissemination. 
